Lucid Capital analyst Dev Prasad initiated coverage of Opus Genetics (IRD) with a Buy rating and $5 price target The company’s lead program, OPGx-LCA5, is being evaluated in a Phase 1/2 trial for LCA5-associated Leber congenital amaurosis, which affects approximately 200 patients in the U.S., the analyst tells investors in a research note. The firm says Interim adult data have shown “encouraging” safety and efficacy results, and the ongoing pediatric cohort could provide additional validation, with initial data from all three pediatric patients expected in Q3.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRD:
- Opus Genetics’ Ryzumvi Shows Promising Phase 3 Results, Reinforcing Buy Rating
- Opus Genetics says LYNX-2 trial met primary endpoint
- Opus Genetics’ Promising Gene Therapy Advances and Strategic Partnerships Reinforce Buy Rating
- Opus Genetics reports Q1 EPS (24c) vs (29c) last year
- Opus Genetics announces upcoming presentations